<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39438600</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Complement activation and lung injury in Japanese patients with COVID-19: a prospective observational study.</ArticleTitle><Pagination><StartPage>24895</StartPage><MedlinePgn>24895</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24895</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-76365-2</ELocationID><Abstract><AbstractText>Background The production of inflammatory cytokines is reportedly increased in patients with coronavirus disease 2019 (COVID-19), causing the migration of neutrophils and monocytes to lung tissues. This disrupts the air-blood barrier by damaging the bronchial epithelial and vascular endothelial cells. As multiorgan dysfunction in sepsis is considered to be partly caused by complement activation, which can cause lung injury in patients with COVID-19. There are limited studies examining the link between complement activation in patients with COVID-19. This study aimed to AQinvestigate the association of complement activation with the pathophysiology of COVID-19. Twenty-seven patients with COVID-19 were enrolled in this study and classified into two groups depending on the indication for mechanical ventilation. Plasma complement factors (C3a, C5a, Ba, and sC5b-9), complement regulators (sCD59 and factor H), interleukin-6 (IL-6), and syndecan-1 levels were measured using Enzyme-linked immunosorbent assay (ELISA). Results: All complement factors and regulators, IL-6, and syndecan-1 levels were significantly elevated in patients with COVID-19 compared with those in healthy controls. C5a and sC5b-9 levels were decreased significantly in the invasive mechanical ventilation (IMV) group compared with those in the non-IMV group. Syndecan-1 levels were significantly increased in the IMV group compared with those in the non-IMV group. Conclusions: Complement activation is an exacerbating factor for lung injury in patients with COVID-19. Complement factors are nonessential predictors of mechanical ventilation; however, syndecan-1 could be a biomarker of COVID-19 severity in patients.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seki</LastName><ForeName>Kentaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sueyoshi</LastName><ForeName>Koichiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan. sueyoshi4897@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyoshi</LastName><ForeName>Yukari</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishihara</LastName><ForeName>Tadashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kondo</LastName><ForeName>Yutaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuroda</LastName><ForeName>Yoko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yonekura</LastName><ForeName>Ayumi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Environmental and Gender Specific Medicine, Juntendo University, Urayasu, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwabuchi</LastName><ForeName>Kazuhisa</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Environmental and Gender Specific Medicine, Juntendo University, Urayasu, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okamoto</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>23K27704</GrantID><Agency>JSPS KAKENHI</Agency><Country /></Grant><Grant><GrantID>19H03764</GrantID><Agency>JSPS KAKENHI</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053668">Syndecan-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003167" MajorTopicYN="Y">Complement Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055370" MajorTopicYN="N">Lung Injury</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053668" MajorTopicYN="N">Syndecan-1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000095225" MajorTopicYN="N">East Asian People</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Complement system</Keyword><Keyword MajorTopicYN="N">Invasive mechanical ventilation</Keyword><Keyword MajorTopicYN="N">Syndecan-1</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>23</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39438600</ArticleId><ArticleId IdType="pmc">PMC11496683</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-76365-2</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-76365-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vabret, N. et al. Immunology of COVID-19: current state of the science. Immunity. 52, 910–941 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7200337</ArticleId><ArticleId IdType="pubmed">32505227</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. &amp; Prescott, H. C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 324, 782–793 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudd, P. A. et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci. Adv. 6, eabe3024 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7725462</ArticleId><ArticleId IdType="pubmed">33187979</ArticleId></ArticleIdList></Reference><Reference><Citation>Fattahi, F., Zetoune, F. S. &amp; Ward, P. A. Complement as a major inducer of harmful events in infectious sepsis. Shock. 54, 595–605 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9704109</ArticleId><ArticleId IdType="pubmed">32187106</ArticleId></ArticleIdList></Reference><Reference><Citation>Rognes, I. N. et al. Increased complement activation 3 to 6 h after trauma is a predictor of prolonged mechanical ventilation and multiple organ dysfunction syndrome: a prospective observational study. Mol. Med. 27, 35 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8028580</ArticleId><ArticleId IdType="pubmed">33832430</ArticleId></ArticleIdList></Reference><Reference><Citation>Burk, A. M. et al. Early complementopathy after multiple injuries in humans. Shock. 37, 348–354 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3306539</ArticleId><ArticleId IdType="pubmed">22258234</ArticleId></ArticleIdList></Reference><Reference><Citation>Rittirsch, D., Redl, H. &amp; Huber-Lang, M. Role of complement in multiorgan failure. Clin. Dev. Immunol. 2012, 962927 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3539671</ArticleId><ArticleId IdType="pubmed">23320021</ArticleId></ArticleIdList></Reference><Reference><Citation>Java, A. et al. The complement system in COVID-19: friend and foe. JCI Insight. 5, e140711 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7455060</ArticleId><ArticleId IdType="pubmed">32554923</ArticleId></ArticleIdList></Reference><Reference><Citation>Holter, J. C. et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc. Natl. Acad. Sci. U S A. 117, 25018–25025 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7547220</ArticleId><ArticleId IdType="pubmed">32943538</ArticleId></ArticleIdList></Reference><Reference><Citation>Skendros, P. et al. Complement and tissue factor–enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J. Clin. Invest. 130, 6151–6157 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598040</ArticleId><ArticleId IdType="pubmed">32759504</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro, C. et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 220, 1–13 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158248</ArticleId><ArticleId IdType="pubmed">32299776</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao, B. et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat. Commun. 12, 2506 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8096808</ArticleId><ArticleId IdType="pubmed">33947851</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramlall, V. et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat. Med. 26, 1609 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7809634</ArticleId><ArticleId IdType="pubmed">32747830</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, L. et al. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Sci. Immunol. 6, eabh2259 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8158979</ArticleId><ArticleId IdType="pubmed">34446527</ArticleId></ArticleIdList></Reference><Reference><Citation>Boussier, J. et al. Severe COVID-19 is associated with hyperactivation of the alternative complement pathway. J. Allergy Clin. Immunol. 149, 550–556e2 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8595971</ArticleId><ArticleId IdType="pubmed">34800432</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackey, K. et al. Racial and ethnic disparities in COVID-19-related infections, hospitalizations, and deaths: a systematic review. Ann. Intern. Med. 174, 362–373 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7772883</ArticleId><ArticleId IdType="pubmed">33253040</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaus, W. A., Draper, E. A., Wagner, D. P. &amp; Zimmerman, J. E. APACHE II: a severity of disease classification system. Crit. Care Med. 13, 818–829 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">3928249</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones, A. E., Trzeciak, S. &amp; Kline, J. A. The sequential organ failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. Crit. Care Med. 37, 1649–1654 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703722</ArticleId><ArticleId IdType="pubmed">19325482</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, X. et al. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clin. Infect. Dis. 71, 1937–1942 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184354</ArticleId><ArticleId IdType="pubmed">32301997</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, J. et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 55, 102763 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165294</ArticleId><ArticleId IdType="pubmed">32361250</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, T. et al. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol. Med. 12, e12421 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280589</ArticleId><ArticleId IdType="pubmed">32428990</ArticleId></ArticleIdList></Reference><Reference><Citation>Chelazzi, C., Villa, G., Mancinelli, P., De Gaudio, A. R. &amp; Adembri, C. Glycocalyx and sepsis-induced alterations in vascular permeability. Crit. Care. 19, 26 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4308932</ArticleId><ArticleId IdType="pubmed">25887223</ArticleId></ArticleIdList></Reference><Reference><Citation>Frati-Munari, A. C. Medical significance of endothelial glycocalyx. Arch. Cardiol. Mex. 83, 303–312 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24280179</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodcock, T. E. &amp; Woodcock, T. M. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br. J. Anaesth. 108, 384–394 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22290457</ArticleId></ArticleIdList></Reference><Reference><Citation>Risitano, A. M. et al. Complement as a target in COVID-19. Nat. Rev. Immunol. 20, 343–344 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187144</ArticleId><ArticleId IdType="pubmed">32327719</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson, B. et al. How the innate immune system of the blood contributes to systemic pathology in COVID-19-induced ARDS and provides potential targets for treatment. Front. Immunol. 13, 840137 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8957861</ArticleId><ArticleId IdType="pubmed">35350780</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo, M. W., Kemper, C. &amp; Woodruff, T. M. COVID-19: complement, coagulation, and collateral damage. J. Immunol. 205, 1488–1495 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484432</ArticleId><ArticleId IdType="pubmed">32699160</ArticleId></ArticleIdList></Reference><Reference><Citation>Detsika, M. G. et al. C3a and C5b-9 differentially predict COVID-19 progression and outcome. Life (Basel). 12, 1335 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9504647</ArticleId><ArticleId IdType="pubmed">36143371</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan, A. E. et al. Prognostic significance of complement factors in severely ill patients with COVID-19. J. Investig Med. 70, 1466–1471 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35940732</ArticleId></ArticleIdList></Reference><Reference><Citation>Charitos, P. et al. Functional activity of the complement system in hospitalized COVID-19 patients: a prospective cohort study. Front. Immunol. 12, 765330 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8581394</ArticleId><ArticleId IdType="pubmed">34777382</ArticleId></ArticleIdList></Reference><Reference><Citation>Gralinski, L. E. et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 9, e01753–e01718 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6178621</ArticleId><ArticleId IdType="pubmed">30301856</ArticleId></ArticleIdList></Reference><Reference><Citation>Tal, Y., Adini, A., Eran, A. &amp; Adini, I. Racial disparity in Covid-19 mortality rates - a plausible explanation. Clin. Immunol. 217, 108481 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7253967</ArticleId><ArticleId IdType="pubmed">32473354</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips, N., Park, I. W., Robinson, J. R. &amp; Jones, H. P. The perfect storm: COVID-19 health disparities in US blacks. J. Racial Ethn. Health Disparities. 8, 1153–1160 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7510013</ArticleId><ArticleId IdType="pubmed">32965660</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, T. et al. Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation. Signal. Transduct. Target. Ther. 7, 318 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9470675</ArticleId><ArticleId IdType="pubmed">36100602</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali, Y. M. et al. Lectin pathway mediates complement activation by SARS-CoV-2 proteins. Front. Immunol. 12, 714511 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8287855</ArticleId><ArticleId IdType="pubmed">34290717</ArticleId></ArticleIdList></Reference><Reference><Citation>Defendi, F. et al. Complement alternative and mannose-binding lectin pathway activation is associated with COVID-19 mortality. Front. Immunol. 12, 742446 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8461024</ArticleId><ArticleId IdType="pubmed">34567008</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada, H., Yoshida, S., Hara, A., Ogura, S. &amp; Tomita, H. Vascular endothelial injury exacerbates coronavirus disease 2019: the role of endothelial glycocalyx protection. Microcirculation. 28, e12654 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7435519</ArticleId><ArticleId IdType="pubmed">32791568</ArticleId></ArticleIdList></Reference><Reference><Citation>Astapenko, D. et al. Endothelial glycocalyx damage in patients with severe COVID-19 on mechanical ventilation – a prospective observational pilot study. Clin. Hemorheol Microcirc. 81, 205–219 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35342082</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelosi, P. &amp; Rocco, P. R. Effects of mechanical ventilation on the extracellular matrix. Intensive Care Med. 34, 631–639 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18264691</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlaar, A. P. J. et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 10, 1137–1146 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9451499</ArticleId><ArticleId IdType="pubmed">36087611</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>